1 / 45

Thyroid Malignancy

Thyroid Malignancy. 39 y/o female from Bicol C/C: anterior neck mass. HPI. ROS. No fever, weight loss and tremors No chest pain and easy fatigability No abdominal pain Past medical and family history both unremarkable. Physical Examination. PR = 100/min RR = 20/min

tokala
Télécharger la présentation

Thyroid Malignancy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Thyroid Malignancy

  2. 39 y/o female from Bicol • C/C: anterior neck mass

  3. HPI

  4. ROS • No fever, weight loss and tremors • No chest pain and easy fatigability • No abdominal pain • Past medical and family history both unremarkable

  5. Physical Examination • PR = 100/min RR = 20/min Temperature = 37 °C • No exophthalmos • Neck: • 12x10 cm multilobulated firm mass on the left neck, moves with deglutition

  6. What is your clinical impression?What are the differential diagnosis?

  7. Differential Diagnoses

  8. Thyroid cancer • Most common malignancy of the endocrine system • Accounts for less than 1% of all malignancies • Common among chinese males & filipino females

  9. Risk factors for thyroid carcinoma in patients with thyroid nodule • History of head & neck irradiation • Age <20 or > 70 y/o • Increased nodule size (>4cm) • New or enlarging neck mass • Male gender

  10. Family history of thyroid cancer or MEN 2 • Vocal cord paralysis, hoarse voice • Nodule fixed to adjacent structures • Suspected lymph node involvement • Iodine deficiency (follicular)

  11. Clinical features: • Lump in the neck • Gradually enlarging mass • Firm or hard • Rapidly growing: soft or fluctuant • May be painful • May present with hoarseness, dysphagia, dysphonia, dyspnea • Rare: hyperthyroidism

  12. Papillary Carcinoma • 80-85% • Predominant: children & individuals exposed to external radiation • 2:1 F:M ratio • Mean age: 30-40 y/o • S/Sx: slow growing painless mass • Dysphagia, dyspnea, dsyphonia • Lymph nodes metastases (common) • Distal mets uncommon (lungs, bone, liver, brain)

  13. Characteristic cellular patterns: Orphan Annie nuclei • Psamomma bodies • Multifocality (85%) • Prognosis: excellent (95% 10 yr survival rate)

  14. Diagnosis • discovered when a hard nodule is found in multinodular goiter • when enlarged cervical lymph nodes are detected • when there are unidentified metastatic lesions elsewhere in the body • Other clinical signs that could indicate papillary thyroid are: • fixation to the trachea, stony hardness, damage to recurrent laryngeal or cervical sympathetic nerves.

  15. Follicular Carcinoma • Second most common (10%) • Iodine deficient areas • 3:1 F:M ratio • Mean age: 50 y/o • Usually solitary (rapid size increase & goiter) • s/sx: pain & cervical lymphadenopathyuncommon initial presentation

  16. 1%: hyperfunctioning - thyrotoxicosis • Solitary & encapsulated • Prognosis: mortality 15% at 10 yrs, 30% at 20 yrs

  17. Hurthle Cell CA • 3-5% • Variant of follicular CA • Vascular or capsular invasion • Multifocal & bilateral • Metastasize to local & distant sites • Higher mortality rate

  18. Medullary CA • 5% • From parafollicular or C cells • 1.5:1 F:M ratio • Mean age: 50-60 y/o • 70-80% are sporadic • 20-30% familial autosomal dominant syndromes

  19. s/sx:neck mass w/ cervical lymphadenopathy - local pain - dysphagia, dyspnea or dysphonia • 2-4%: Cushing’s syndrome • Unilateral (sporadic); multicentric (familial) • Presence of amyloid • Prognosis: related to disease stage

  20. Anaplastic CA • 1% • F>M • Mean age: 65 y/o • s/sx: rapidly enlarging, long standing neck mass, painful - dysphonia, dysphagia, dyspnea • Tumor: large, hard, poorly circumscribed & fixed

  21. Palpable lymph nodes • Metastatic spread • Prognosis: one of the most aggressive, few survive beyond 6 months

  22. Lymphoma • <1% • Most: Non-Hodgkin’s B-cell type • 2-3xF>M • Age: 62 y/o • Patients with chronic lymphocytic thyroiditis • Prognosis: overall 5 yr survival rate: 50%

  23. 2. What work ups are needed, if any?

  24. Evaluation of a Thyroid Nodule • History • Risk factors for thyroid cancer • History of thyroid irradiation, especially in infancy or childhood • Age < 20 yr • Male sex • Family history of thyroid cancer or multiple endocrine neoplasia • A solitary nodule • Dysphagia • Dysphonia • Increasing size (particularly rapid growth or growth while receiving thyroid suppression treatment) • Physical Examination • Signs that suggest thyroid cancer • stony hard consistency or fixation to surrounding structures • cervical lymphadenopathy • hoarseness due to recurrent laryngeal nerve paralysis

  25. Testing

  26. Testing • Fine-Needle Aspiration Biopsy (FNAB) • Cornerstone in the evaluation of solitary thyroid nodules and also dominant nodules within multinodular goiters • Currently considered to be the best first-line diagnostic procedure in the evaluation of the thyroid nodule

  27. Fine-Needle Aspiration Biopsy • Advantages: • Safe • Cost-effective • Minimally invasive • Leads to better selection of patients for surgery than any other test (Rojeski, 1985) • Halved the number of patients requiring thyroidectomy (Mazzaferri, 1993) • Double the yield of cancer in those who do undergo thyroidectomy (Mazzaferri, 1993)

  28. Fine-Needle Aspiration Biopsy • Four Categories of Cytologic Diagnosis • Benign (Negative) – 69% • Suspicious (Indeterminate) – 10% • Malignant (Positive) – 4% • Unsatisfactory (Nondiagnostic) – 17% Reference: Gharib, H. (2008). Fine-Needle Aspiration Biopsy of the Thyroid Gland. Thyroid Disease Manager.

  29. Fine-Needle Aspiration Biopsy • Limitations • Skill of the aspirator • Expertise of the cytologist • Difficulty in distinguishing some benign cellular adenomas from their malignant counterparts (follicular and Hurthle cell) • Sensitivity: 65 – 98% (avg. 83%) • Specificity: 72 – 100% (avg. 92%) • Positive Predictive Value: 50 – 96% (avg. 75%) • False-negative Rates: 1.5 – 11.5% (avg. < 5%) • False-positive Rates: 0 – 8% (avg. 3%) Reference: Gharib, H. (2008). Fine-Needle Aspiration Biopsy of the Thyroid Gland. Thyroid Disease Manager.

  30. CT/MRI

  31. Low risk: Younger patients (men =/< 40, women =/< 50) with no metastases Older patients (intrathyroid papillary, minor capsular invasion for follicular lesions) Primary cancers <5 cm AMES No distant metastases High risk: All patients with distant metastases Extrathyroid papillary, major capsularinvasion follicular Primary cancers >/= 5 cm in older patients(men >40, women >50) Survival by AMES risk-groups (20-yr):    Low risk = 99%    High risk = 61%

  32. MAICS

  33. AMES

  34. Surgical Treatment: Papillary CA High risk or bilateral tumors: Total or near - total thyroidectomy Minimal Papillary Thyroid Tumor Unilateral lobectomy and isthmusectomy

  35. Total Thyroidectomy Unilateral Lobectomy • Enables the use of RAI for detecting and treating residual thyroid tissue and metastatic disease. • Makes serum Tg level a more sensitive marker of recurrent or persistent disease • Eliminates contralateral occult cancer as sites of recurrence • Reduces risk of recurrence • Increases survival • Decreases 1% risk of progression to ATC • Reduces need for reoperative surgery • Lower complication rate • Recurrence is unusual (5%) • Excellent prognosis

  36. Why Thyroidectomy? • Recurrence rates are lowered and survival is improved when a patient underwent thyroidectomy • Diminished survival was noted in patients with low-risk disease

  37. Total Thyroidectomy • Enables the use of RAI for detecting and treating residual thyroid tissue and metastatic disease. • Makes serum Tg level a more sensitive marker of recurrent or persistent disease • Eliminates contralateral occult cancer as sites of recurrence • Reduces risk of recurrence • Increases survival • Decreases 1% risk of progression to ATC • Reduces need for reoperative surgery

  38. Rationale for total thyroidectomy 1) 30%-87.5% of papillary carcinomas involve opposite lobe (Hirabayashi, 1961, Russell, 1983) 2) 7%-10% develop recurrence in the contralateral lobe (Soh, 1996) 3) Lower recurrence rates, some studies show increased survival (Mazzaferri, 1991) 4) Facilitates earlier detection and tx for recurrent or metastatic carcinoma with RAI (Soh, 1996) 5) Residual WDTC has the potential to dedifferentiate to ATC

  39. Indications for total thyroidectomy 1) Patients older than 40 years with papillary or follicular carcinoma 2) Anyone with a thyroid nodule with a history of irradiation 3) Patients with bilateral disease

  40. Rationale for subtotal thyroidectomy 1) Lower incidence of complications • Hypoparathyroidism (1%-29%) (Schroder, 1993) • Recurrent laryngeal nerve injury (1%-2%) (Schroder, 1993) • Superior laryngeal nerve injury 2) Long term prognosis is not improved by total thyroidectomy (Grant, 1988)

  41. Complications • Injury to RLN, Superior Laryngeal Nerve • Transient hypocalcemia (50%) • Permanent hypoparathyroidism (<2%) • Postoperative hematoma • Bilateral vocal cord dysfunction

  42. Postoperative Management of Differentiated Thyroid Cancer • Thyroid Hormone • After thyroidectomy, should placed on thyroxine to ensure that the patient remains euthyroid • serves as a replacement therapy and also suppresses TSH • reduces growth stimulus to possible residual cancer cells • reduces recurrence rates (papillary ca) • risk of tumor recurrence must be balanced with the side effects associated with prolonged TSH suppression, including osteopenia and cardiac problems, particularly in older patients

  43. Postoperative Management of Differentiated Thyroid Cancer • Thyroglobulin Measurement • levels in patients who have undergone total thyroidectomy should be below 2 ng/mL when the patient is taking T4, and below 5 ng/mL when the patient is hypothyroid • level above 5ng/mL is highly suggestive of metastatic disease or persistent normal thyroid tissue. In this situation, radioiodine scan should be performed. • Measure serum levels every 6 months, and then annually if the patient is clinically disease free • Level >30 ng/ml is abnormal • High-risk patients should also have an ultrasound of the neck and CT or MRI scan of the neck and mediastinum for early detection of any persistent or recurrent disease.

  44. Postoperative Management of Differentiated Thyroid Cancer • Radioiodine Therapy • I-131 whole body scan to detect residual normal thyroid tissue &/or metastatic disease • Metastatic differentiated thyroid carcinoma can be detected and treated by radioactive iodine in about 75 % of patients. • Administration • Scan at 4-6 weeks postoperatively • repeat scan at 6-12 months after ablation • repeat scan at 1 year then... • every 2 years thereafter • External Beam Radiotherapy and Chemotherapy • External beam radiotherapy is required occasionally to control unresectable locally invasive or recurrent disease • It also is of value for the treatment and control of pain from bony metastases when there is no appreciable radioiodine uptake.

More Related